Actavis, Cephalon pay-for-delays remain in FTC's bull's-eye
This article was originally published in Scrip
Executive Summary
You've been forewarned, US drug makers. Now more than ever, your reverse-payment settlements remain in the bull's-eye of the Federal Trade Commission (FTC), which is taking sharper aim at the deals with renewed vigor after the US Supreme Court last month declared the agreements subject to antitrust scrutiny.